REG - Oxford Biomedica PLC - Form 8 - Oxford Biomedica plc
27/01/2026 13:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260127:nRSa5885Qa&default-theme=true
RNS Number : 5885Q Oxford Biomedica PLC 27 January 2026
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Oxford Biomedica plc ("OXB")
(b) Owner or controller of interests and short positions disclosed, if N/A
different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a
trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form Oxford Biomedica plc
relates:
Use a separate form for each offeror/offeree
(d) Is the discloser the offeror or the offeree? Offeree
(e) Date position held: 26 January 2026
The latest practicable date prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser making N/A
disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security: Ordinary Shares of 50p each
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: Nil Nil Nil Nil
(2) Cash-settled derivatives: Nil Nil Nil Nil
(3) Stock-settled derivatives (including options) and agreements to Nil Nil Nil Nil
purchase/sell:
Nil Nil Nil Nil
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial
collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: None
Details, including nature of the rights concerned and relevant percentages: None
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO
THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including
directors' and other employee options) of any person acting in concert with
the party to the offer making the disclosure:
Interests of Directors
OXB ordinary shares held by directors of OXB and their close relatives and
related trusts
Director Number of OXB ordinary shares held Percentage of total issued share capital*
Dr. Roch Doliveux 438,805 0.36%
Dr. Frank Mathias 20,000 0.01%
Professor Dame 1,000 0.00%
Kay Davies
Namrata P Patel 9,170 0.00%
Dr. Heather Preston 35,862 0.02%
Total 504,837 0.41%
*Percentages have been given to two decimal places.
Interests held as options or awards by directors of OXB in ordinary shares of
OXB
Director Share plan Grant date Number of OXB ordinary shares in respect of which options granted / subject to Exercise price (per share) (£) Vesting Date Date of expiry of exercise period
award
Dr. Frank Mathias 2015 Long Term Incentive Plan* 04/10/2023 323,178 0.00 04/10/2026 04/10/2033
2024 Long Term Incentive Plan* 03/10/2024 257,113 0.00 03/10/2027 03/10/2034
2024 Long Term Incentive Plan* 16/05/2025 350,204 0.00 16/05/2028 16/05/2035
2024 Deferred Bonus Plan** 16/05/2025 70,803 0.00 T1 16/05/2026 16/05/2035
T2
16/05/2027
T3
16/05/2028
Dr. Lucinda Crabtree 2024 Long Term Incentive Plan* 03/10/2024 170,113 0.00 03/10/2027 03/10/2034
2024 Long Term Incentive Plan* 16/05/2025 201,095 0.00 16/05/2028 16/05/2035
2024 Deferred Bonus Plan** 16/05/2025 15,733 0.00 T1 16/05/2026 16/05/2035
T2
16/05/2027
T3
16/05/2028
* The vesting of the 2015 and 2024 Long Term Incentive Plan award is subject
to the achievement of performance conditions and a two‑year holding period
following the vesting date.
** Deferred Bonus Plan vests in three equal tranches.
*Percentages have been given to two decimal places.
Interests held as options or awards by directors of OXB in ordinary shares of
OXB
Director Share plan Grant date Number of OXB ordinary shares in respect of which options granted / subject to Exercise price (per share) (£) Vesting Date Date of expiry of exercise period
award
Dr. Frank Mathias 2015 Long Term Incentive Plan* 04/10/2023 323,178 0.00 04/10/2026 04/10/2033
2024 Long Term Incentive Plan* 03/10/2024 257,113 0.00 03/10/2027 03/10/2034
2024 Long Term Incentive Plan* 16/05/2025 350,204 0.00 16/05/2028 16/05/2035
2024 Deferred Bonus Plan** 16/05/2025 70,803 0.00 T1 16/05/2026 16/05/2035
T2
16/05/2027
T3
16/05/2028
Dr. Lucinda Crabtree 2024 Long Term Incentive Plan* 03/10/2024 170,113 0.00 03/10/2027 03/10/2034
2024 Long Term Incentive Plan* 16/05/2025 201,095 0.00 16/05/2028 16/05/2035
2024 Deferred Bonus Plan** 16/05/2025 15,733 0.00 T1 16/05/2026 16/05/2035
T2
16/05/2027
T3
16/05/2028
* The vesting of the 2015 and 2024 Long Term Incentive Plan award is subject
to the achievement of performance conditions and a two‑year holding period
following the vesting date.
** Deferred Bonus Plan vests in three equal tranches.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial
collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the party to
the offer making the disclosure or any person acting in concert with it:
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
None.
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the party to the offer making the disclosure, or any person acting in
concert with it, and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None.
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
Date of disclosure: 27 January 2026
Contact name: Natalie Walter, Chief Legal Officer and Group Company Secretary
Telephone number: +44 (0) 1865 783 000
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FEEEADFXAAXKEFA
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Oxford BioMedica
See all newsRCS - Oxford Biomedica PLC - Launch of viral vector fast-track offering
AnnouncementREG - Oxford Biomedica PLC - Grant of Awards
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2026 Annual General Meeting notification
AnnouncementREG - Oxford Biomedica PLC - Preliminary results for the year ended 31 Dec 2025
Announcement